A Chinese biotech firm has skyrocketed more than 4,500% in the three months since its Hong Kong debut, stoking worries of speculative buying.


Source: Bloomberg Markets.


Leave a Reply

Your email address will not be published. Required fields are marked *

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

The reCAPTCHA verification period has expired. Please reload the page.